A novel mouse model for de novo melanoma

Mayuko Y. Kumasaka, Ichiro Yajima, Khaled Hossain, Machiko Iida, Toyonori Tsuzuki, Tamio Ohno, Masahide Takahashi, Masashi Yanagisawa, Masashi Kato

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Nevus-associated melanomas arise from pre-existing benign lesions, but de novo melanomas can also develop in the absence of such lesions. Few studies have addressed the latter phenomenon because no animal models have been described in which melanomas clearly develop in a de novo manner. In this study, we have address this need in defining RFP-RET-transgenic mice (RET mice) as a mouse model for multi-step melanomagenesis that proceeds via tumor-free, benign, premalignant, and malignant stages. Melanomas from RET mice exhibited decreased expression levels of endothelin receptor B (Ednrb) compared with benign tumors. In RET mice that were heterozygous for Ednrb (Ednrb+/-;RET mice), >80% of the arising primary tumors were malignant. Life span after tumor development in the mice was significantly shorter than in RET mice. Lung metastasis after tumor development was significantly higher than in RET mice. The observed process of melanomagenesis in Ednrb+/-;RET mice, which proceeded without a pre-existing benign lesion, along with the emergent characteristics in the model after tumor development corresponded well with the formation of de novo melanoma in humans. Our findings define a novel transgenic mouse model for de novo melanoma and suggest that reduced expression of Ednrb might facilitate the development of de novo melanoma in humans.

Original languageEnglish
Pages (from-to)24-29
Number of pages6
JournalCancer Research
Volume70
Issue number1
DOIs
Publication statusPublished - 2010 Jan 1
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kumasaka, M. Y., Yajima, I., Hossain, K., Iida, M., Tsuzuki, T., Ohno, T., ... Kato, M. (2010). A novel mouse model for de novo melanoma. Cancer Research, 70(1), 24-29. https://doi.org/10.1158/0008-5472.CAN-09-2838

A novel mouse model for de novo melanoma. / Kumasaka, Mayuko Y.; Yajima, Ichiro; Hossain, Khaled; Iida, Machiko; Tsuzuki, Toyonori; Ohno, Tamio; Takahashi, Masahide; Yanagisawa, Masashi; Kato, Masashi.

In: Cancer Research, Vol. 70, No. 1, 01.01.2010, p. 24-29.

Research output: Contribution to journalArticle

Kumasaka, MY, Yajima, I, Hossain, K, Iida, M, Tsuzuki, T, Ohno, T, Takahashi, M, Yanagisawa, M & Kato, M 2010, 'A novel mouse model for de novo melanoma', Cancer Research, vol. 70, no. 1, pp. 24-29. https://doi.org/10.1158/0008-5472.CAN-09-2838
Kumasaka MY, Yajima I, Hossain K, Iida M, Tsuzuki T, Ohno T et al. A novel mouse model for de novo melanoma. Cancer Research. 2010 Jan 1;70(1):24-29. https://doi.org/10.1158/0008-5472.CAN-09-2838
Kumasaka, Mayuko Y. ; Yajima, Ichiro ; Hossain, Khaled ; Iida, Machiko ; Tsuzuki, Toyonori ; Ohno, Tamio ; Takahashi, Masahide ; Yanagisawa, Masashi ; Kato, Masashi. / A novel mouse model for de novo melanoma. In: Cancer Research. 2010 ; Vol. 70, No. 1. pp. 24-29.
@article{f4612f4eaa154711a0dc8326a78d4e2e,
title = "A novel mouse model for de novo melanoma",
abstract = "Nevus-associated melanomas arise from pre-existing benign lesions, but de novo melanomas can also develop in the absence of such lesions. Few studies have addressed the latter phenomenon because no animal models have been described in which melanomas clearly develop in a de novo manner. In this study, we have address this need in defining RFP-RET-transgenic mice (RET mice) as a mouse model for multi-step melanomagenesis that proceeds via tumor-free, benign, premalignant, and malignant stages. Melanomas from RET mice exhibited decreased expression levels of endothelin receptor B (Ednrb) compared with benign tumors. In RET mice that were heterozygous for Ednrb (Ednrb+/-;RET mice), >80{\%} of the arising primary tumors were malignant. Life span after tumor development in the mice was significantly shorter than in RET mice. Lung metastasis after tumor development was significantly higher than in RET mice. The observed process of melanomagenesis in Ednrb+/-;RET mice, which proceeded without a pre-existing benign lesion, along with the emergent characteristics in the model after tumor development corresponded well with the formation of de novo melanoma in humans. Our findings define a novel transgenic mouse model for de novo melanoma and suggest that reduced expression of Ednrb might facilitate the development of de novo melanoma in humans.",
author = "Kumasaka, {Mayuko Y.} and Ichiro Yajima and Khaled Hossain and Machiko Iida and Toyonori Tsuzuki and Tamio Ohno and Masahide Takahashi and Masashi Yanagisawa and Masashi Kato",
year = "2010",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-09-2838",
language = "English",
volume = "70",
pages = "24--29",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - A novel mouse model for de novo melanoma

AU - Kumasaka, Mayuko Y.

AU - Yajima, Ichiro

AU - Hossain, Khaled

AU - Iida, Machiko

AU - Tsuzuki, Toyonori

AU - Ohno, Tamio

AU - Takahashi, Masahide

AU - Yanagisawa, Masashi

AU - Kato, Masashi

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Nevus-associated melanomas arise from pre-existing benign lesions, but de novo melanomas can also develop in the absence of such lesions. Few studies have addressed the latter phenomenon because no animal models have been described in which melanomas clearly develop in a de novo manner. In this study, we have address this need in defining RFP-RET-transgenic mice (RET mice) as a mouse model for multi-step melanomagenesis that proceeds via tumor-free, benign, premalignant, and malignant stages. Melanomas from RET mice exhibited decreased expression levels of endothelin receptor B (Ednrb) compared with benign tumors. In RET mice that were heterozygous for Ednrb (Ednrb+/-;RET mice), >80% of the arising primary tumors were malignant. Life span after tumor development in the mice was significantly shorter than in RET mice. Lung metastasis after tumor development was significantly higher than in RET mice. The observed process of melanomagenesis in Ednrb+/-;RET mice, which proceeded without a pre-existing benign lesion, along with the emergent characteristics in the model after tumor development corresponded well with the formation of de novo melanoma in humans. Our findings define a novel transgenic mouse model for de novo melanoma and suggest that reduced expression of Ednrb might facilitate the development of de novo melanoma in humans.

AB - Nevus-associated melanomas arise from pre-existing benign lesions, but de novo melanomas can also develop in the absence of such lesions. Few studies have addressed the latter phenomenon because no animal models have been described in which melanomas clearly develop in a de novo manner. In this study, we have address this need in defining RFP-RET-transgenic mice (RET mice) as a mouse model for multi-step melanomagenesis that proceeds via tumor-free, benign, premalignant, and malignant stages. Melanomas from RET mice exhibited decreased expression levels of endothelin receptor B (Ednrb) compared with benign tumors. In RET mice that were heterozygous for Ednrb (Ednrb+/-;RET mice), >80% of the arising primary tumors were malignant. Life span after tumor development in the mice was significantly shorter than in RET mice. Lung metastasis after tumor development was significantly higher than in RET mice. The observed process of melanomagenesis in Ednrb+/-;RET mice, which proceeded without a pre-existing benign lesion, along with the emergent characteristics in the model after tumor development corresponded well with the formation of de novo melanoma in humans. Our findings define a novel transgenic mouse model for de novo melanoma and suggest that reduced expression of Ednrb might facilitate the development of de novo melanoma in humans.

UR - http://www.scopus.com/inward/record.url?scp=75149129051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149129051&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-2838

DO - 10.1158/0008-5472.CAN-09-2838

M3 - Article

C2 - 20048069

AN - SCOPUS:75149129051

VL - 70

SP - 24

EP - 29

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -